Drugs & Targets EU CHMP adopts positive opinion for Cabometyx in radioactive iodine-refractory differentiated thyroid cancer April 01, 2022Vol.48 No.13
Drugs & Targets CHMP adopts positive opinion for Kymriah in relapsed or refractory follicular lymphoma April 01, 2022Vol.48 No.13
Drugs & Targets Thermo Fisher Scientific’s CE-IVD marked next-gen sequencing instrument available for use in clinical labs April 01, 2022Vol.48 No.13
Drugs & Targets Paige launches AI software to enable accurate and efficient detection of breast cancer metastases in lymph nodes April 01, 2022Vol.48 No.13
Drugs & Targets FDA approves Opdualag for unresectable or metastatic melanoma March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves Pluvicto for metastatic castration-resistant prostate cancer March 25, 2022Vol.48 No.12
Drugs & Targets PathAI, Cleveland Clinic to build digital pathology infrastructure, support use of AI-powered pathology algorithms in research and clinical care March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves FoundationOne CDx as companion diagnostic for EGFR therapeutics targeting exon 19 deletions or exon 21 substitutions in NSCLC March 18, 2022Vol.48 No.11
Drugs & Targets Strata Oncology Sentinel Trial for personalized cancer recurrence monitoring enrolls first patient March 18, 2022Vol.48 No.11
Drugs & Targets FDA approves Opdivo and platinum-doublet chemotherapy for early-stage NSCLC March 11, 2022Vol.48 No.10
